Browsing: Therapeutics

Lut Ming ChengJPMorgan Chase & Co, Research Division Good afternoon, everyone. Thanks for joining us for another session at the 44th JPMorgan Healthcare Conference. I’m Brian…

Lut Ming ChengJPMorgan Chase & Co, Research Division Good morning, everyone. Thanks for joining us for another session at the 44th JPMorgan Healthcare Conference. I’m Brian…

Jessica FyeJPMorgan Chase & Co, Research Division Great. Good afternoon, everyone. My name is Jess Fye, large-cap biotech analyst at JPMorgan, and we’re continuing the 44th…

This article was written byFollowI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a…

This article was written byFollowI am a full-time analyst interested in a wide range of stocks. With my unique insights and knowledge, I hope to provide…

Major U.S. stock indices closed higher Tuesday, with the Dow Jones Industrial Average up 0.16% at 48,442.41, the S&P 500 advancing 0.46% to 6,909.79, and the…

Nektar Therapeutics (NASDAQ:NKTR) stock is trading lower Monday afternoon as the market continues to assess mixed topline results from the Phase 2b REZOLVE-AA trial of rezpegaldesleukin.…

This article was written byFollowWith a background as a RN, I analyze healthcare-related stocks by evaluating clinical data, treatment guidelines, and market dynamics. After completing my…

FollowPlay Earnings CallPlay Earnings Call 4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential December 17,…

Michelle CorralVice President of Investor Relationship & Corporate Communications Hi, everyone, and thank you for joining us today. I’m Michelle Corral, Vice President of Corporate Communications…